|Application:||Gene expression microarray analysis|
|Number of samples:||12|
|Release date:||May 28 2018|
|Last update date:||Aug 13 2018|
|Diseases:||Sleep Initiation and Maintenance Disorders, Neoplasms|
|Dataset link||Deacetylation of miRNA-34a and miRNA-449 induce epithelial-mesenchymal transition and acquired resistance to ALK inhibitors|
For in vivo model, mice with established H3122-derived tumors were treated with four doses of ceritinib (control, 75mg/kg, 87.5mg/kg, 100mg/kg) to derive ceritinib-resistant tumors. Xenograft tumors showed initial dose-dependent decrease in tumor volume and subsequently developed acquired resistance within 24-108 days.